Market Overview

Robbins Arroyo LLP: MabVax Therapeutics Holdings, Inc. (MBVX) Misled Shareholders According to a Recently Filed Class Action


Shareholder rights law firm Robbins
Arroyo LLP
announces that purchasers of MabVax Therapeutics
Holdings, Inc. (OTC:MBVX) have filed a class action complaint
against the company's officers and directors for alleged violations of
the Securities Exchange Act of 1934 between June 30, 2014 and May 18,
2018. MabVax, a clinical stage biopharmaceutical company, discovers,
develops, and commercializes proprietary human monoclonal antibody
products and vaccines for the treatment of various cancers.

View this information on the law firm's Shareholder Rights Blog:

MabVax Accused of Incorrectly Calculating Beneficial Ownership of
MabVax Shares

On January 30, 2018, MabVax disclosed that it was being investigated by
the SEC related to certain registration statements. Then, on May 21,
2018, MabVax revealed that the SEC was also investigating potential
violations of securities laws by the company's officers, directors, and
holders of the company's securities. MabVax stated that the
investigation raised questions about the accuracy of certain stockholder
reports that MabVax used to calculate and report beneficial ownership.
MabVax also noted that if those reports were inaccurate, this would have
a domino effect, causing several other figures in its financial
statements to be inaccurate. Since news of the SEC investigation was
made public, MabVax's stock fell over 48% to close at $1.36 per share on
May 21, 2018. The company's stock has since plummeted even further,
trading at only $0.46 per share on August 7, 2018.

MabVax Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!